Candel Therapeutics CFO Jason Amello resigns; Charles Schoch appointed interim CFO

Candel Therapeutics, Inc.

Jason Amello resigned as CFO, principal financial and accounting officer, effective January 12, 2024, to pursue another opportunity.
Resignation not due to any disagreement with auditors or company on operations, policies, or financial disclosures.
Charles Schoch, VP of Finance and Corporate Controller, will serve as Interim CFO while a permanent replacement is sought.
Amello will remain as an advisor to support transition of responsibilities.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Charles Schoch

Interim Chief Financial Officer

CADL · Candel Therapeutics, Inc.

Effective: 2024-01-12
Filed: December 15, 2023, 6:59 PM ET

Effective upon Mr. Amello’s cessation of service as Chief Financial Officer, the Company intends to appoint Charles Schoch, the Company’s current Vice President of Finance and Corporate Controller, as the Company’s Interim Chief Financial Officer, principal financial and principal accounting officer while the Company engages in a search for a permanent replacement for Mr. Amello.

Departed

Jason A. Amello

Chief Financial Officer

CADL · Candel Therapeutics, Inc.

Effective: 2024-01-12
Successor: Charles Schoch
Filed: December 15, 2023, 6:59 PM ET

On December 11, 2023, Jason A. Amello notified Candel Therapeutics, Inc. (the “Company”) of his decision to resign from his position as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective January 12, 2024, to pursue another opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Charles Schoch was appointed as Interim Chief Financial Officer at Candel Therapeutics, Inc..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

Effective upon Mr. Amello’s cessation of service as Chief Financial Officer, the Company intends to appoint Charles Schoch, the Company’s current Vice President of Finance and Corporate Controller, as the Company’s Interim Chief Financial Officer, principal financial and principal accounting officer while the Company engages in a search for a permanent replacement for Mr. Amello.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jason A. Amello resigned as Chief Financial Officer at Candel Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On December 11, 2023, Jason A. Amello notified Candel Therapeutics, Inc. (the “Company”) of his decision to resign from his position as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective January 12, 2024, to pursue another opportunity.

View on SEC.gov

Candel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-070509

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.